These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11642692)

  • 1. Integrating fluoroquinolones into the hospital formulary.
    Bertino JS
    Pharmacotherapy; 2001 Oct; 21(10 Pt 2):273S-283S. PubMed ID: 11642692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulary management of macrolide antibiotics.
    Guay DR
    Pharmacoeconomics; 1995 Dec; 8(6):491-512. PubMed ID: 10160079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
    Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulary considerations in selection of beta-blockers.
    Yedinak KC
    Pharmacoeconomics; 1993 Aug; 4(2):104-21. PubMed ID: 10150154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gatifloxacin: a review of its use in the management of bacterial infections.
    Perry CM; Ormrod D; Hurst M; Onrust SV
    Drugs; 2002; 62(1):169-207. PubMed ID: 11790160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Moxifloxacin--antimicrobial activity and pharmacokinetic properties].
    Iakovlev VP; Polushkina NR
    Antibiot Khimioter; 2002; 47(5):19-29. PubMed ID: 12365324
    [No Abstract]   [Full Text] [Related]  

  • 7. [Trovafloxacin].
    Azanza JR; Ollero D; Sádaba B; García Quetglas E
    Rev Med Univ Navarra; 1999; 43(1):45-57. PubMed ID: 10386346
    [No Abstract]   [Full Text] [Related]  

  • 8. Maintaining fluoroquinolone class efficacy: review of influencing factors.
    Scheld WM
    Emerg Infect Dis; 2003 Jan; 9(1):1-9. PubMed ID: 12533274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current challenges in the treatment of complicated urinary tract infections and prostatitis.
    Wagenlehner FM; Naber KG
    Clin Microbiol Infect; 2006 May; 12 Suppl 3():67-80. PubMed ID: 16669930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The fluoroquinolones.
    Walker RC
    Mayo Clin Proc; 1999 Oct; 74(10):1030-7. PubMed ID: 10918871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinolones: clinical use and formulary considerations.
    Cunha BA
    Adv Ther; 1998; 15(5):277-87. PubMed ID: 10345149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose intravenous fluoroquinolones in the treatment of severe infections.
    Modai J
    J Chemother; 1999 Dec; 11(6):478-85. PubMed ID: 10678789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolones: use of clinical data to aid formulary choice by the system of objective judgement analysis (SOJA) method.
    Janknegt R
    Pharmacoeconomics; 1994 Jul; 6(1):15-33. PubMed ID: 10147351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antibacterial activity and pharmacodynamics of new quinolones.
    Dalhoff A; Schmitz FJ
    Eur J Clin Microbiol Infect Dis; 2003 Apr; 22(4):203-21. PubMed ID: 12687416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of quinolones in hospitals and the community.
    Davey P
    Drugs; 1999; 58 Suppl 2():71-7. PubMed ID: 10553710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections.
    Carson C; Naber KG
    Drugs; 2004; 64(12):1359-73. PubMed ID: 15200349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.
    Davis R; Markham A; Balfour JA
    Drugs; 1996 Jun; 51(6):1019-74. PubMed ID: 8736621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximizing efficacy and reducing the emergence of resistance.
    Wise R
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():37-42. PubMed ID: 12702702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preserving the efficacy of front-line fluoroquinolones through selective use to optimise clinical outcomes.
    Lode HM
    Int J Antimicrob Agents; 2014 Jun; 43(6):497-507. PubMed ID: 24787481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF; Goa KL
    Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.